Clinical and biological characteristics of myelodysplastic syndromes with nulisomy Y by FISH

被引:0
|
作者
GarciaIsidoro, M
Tabernero, MD
Najera, ML
Garcia, JL
Hernandez, JM
Duran, A
SanMiguel, JF
Orfao, A
机构
[1] UNIV HOSP, HEMATOL LAB, SERV CITOMETRIA, SALAMANCA 37007, SPAIN
[2] UNIV SALAMANCA, DEPT MED, SERV CITOMETRIA, E-37008 SALAMANCA, SPAIN
关键词
cytogenetics; FISH; myelodysplastic syndromes; nulisomy Y;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective. In the present study we analyzed the incidence of nulisomy Y by fluorescence in situ hybridization in a group of 24 males diagnosed with myelodysplastic syndromes (MDS). We explored the relationship between this chromosome abnormality and other clinical and biological disease characteristics. Methods. Loss of chromosome Y was present in 7 out of the 24 males analyzed (29%); the number of cells carrying this chromosome aberration ranged between 19% and 90%. From the clinico-biological point of view, the group of patients with nulisomy Y showed a higher incidence of RA and RAS FAB subtypes (p=0.04), a lower WBC count (p=0.04), a lower proportion of blast cells both in PB (p=0.009) and BM (p=0.06) associated with a decreased myeloid/erythroid ratio (p=0.01). Results. No clear association was detected between loss of chromosome Y and other numerical chromosome abnormalities involving chromosomes 7 and 8. In contrast, 2 out of the 7 cases with loss of chromosome Y also displayed monosomy 1 by FISH. However, the use of appropriate dual stainings showed that these two abnormalities were present in different cell populations (that is, they never coexisted in the same cell population), which supports the notion of the existence of clonal heterogeneity in MDS patients. Interpretation and Conclusions. From the prognostic point of view, MDS patients with loss of chromosome Y displayed a higher survival rate, although these differences did not reach statistical significance. (C) 1997, Ferrata Storti Foundation.
引用
收藏
页码:537 / 541
页数:5
相关论文
共 50 条
  • [31] Clinical aspects, cytogenetics and disease evolution in myelodysplastic syndromes
    Ohyashiki, K
    Ohyashiki, JH
    Iwabuchi, A
    Toyama, K
    LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 409 - 415
  • [32] Myelodysplastic syndromes. Molecular background and clinical implications
    Mueller, N. Z.
    Hofmann, W. -K.
    Nolte, F.
    ONKOLOGE, 2012, 18 (12): : 1120 - 1129
  • [33] Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
    Finelli, Carlo
    Follo, Matilde Y.
    Stanzani, Marta
    Parisi, Sarah
    Clissa, Cristina
    Mongiorgi, Sara
    Barraco, Marilena
    Cocco, Lucio
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (16) : 2349 - 2357
  • [34] Biological implications of circulating CD34+ cells in myelodysplastic syndromes
    Marisavljevic, D.
    Kraguljac-Kurtovic, N.
    JOURNAL OF BUON, 2010, 15 (04): : 753 - 757
  • [35] Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings
    Rigolin, GM
    Della Porta, M
    Bugli, AM
    Castagnari, B
    Mauro, E
    Bragotti, LZ
    Ciccone, M
    Cuneo, A
    Castoldi, G
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 73 (05) : 351 - 358
  • [36] Bone marrow lymphoid aggregates in myelodysplastic syndromes: incidence, immunomorphological characteristics and correlation with clinical features and survival
    Magalhaes, SMM
    Rocha, FD
    Vassallo, J
    Pinheiro, MP
    Metze, K
    Lorand-Metze, I
    LEUKEMIA RESEARCH, 2002, 26 (06) : 525 - 530
  • [37] Cytogenetic characteristics in Vietnamese patients diagnosed with primary myelodysplastic syndromes
    Vu, Minh Phuong
    Ha, Hong Quang
    Nguyen, Cuc Nhung
    LEUKEMIA RESEARCH REPORTS, 2022, 18
  • [38] Comparative Characteristics of Cytogenetic Abnormalities in Different Types of Myelodysplastic Syndromes
    S. V. Andreieva
    K. V. Korets
    I. M. Skorohod
    H. S. Starodub
    Cytology and Genetics, 2022, 56 : 423 - 430
  • [39] Comparative Characteristics of Cytogenetic Abnormalities in Different Types of Myelodysplastic Syndromes
    Andreieva, S., V
    Korets, K., V
    Skorohod, I. M.
    Starodub, H. S.
    CYTOLOGY AND GENETICS, 2022, 56 (05) : 423 - 430
  • [40] CLINICAL AND CYTOGENETIC FINDINGS OF MYELODYSPLASTIC SYNDROMES SHOWING HYPOCELLULAR BONE-MARROW OR MINIMAL DYSPLASIA, IN COMPARISON WITH TYPICAL MYELODYSPLASTIC SYNDROMES
    TOYAMA, K
    OHYASHIKI, K
    YOSHIDA, Y
    ABE, T
    ASANO, S
    HIRAI, H
    HIRASHIMA, K
    HOTTA, T
    KURAMOTO, A
    KURIYA, S
    MIYAZAKI, T
    KAKISHITA, E
    MIZOGUCHI, H
    MORI, M
    SHIRAKAWA, S
    TAKAKU, F
    TOMONAGA, M
    UCHINO, H
    URABE, A
    YASUNAGA, K
    NOMURA, T
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1993, 58 (1-2) : 53 - 61